Why This Summit Is Unmissable for Biotech Drug Developers
Advance Your RNA-Targeted Small Molecule Programs With Insights From Industry Leaders.
Whether you're validating new RNA targets, advancing lead compounds, or progressing toward IND-enabling studies, this is the only forum dedicated exclusively to RNA-targeted small molecules.
Join the companies leading the field as they share new data, lessons learned, and emerging strategies across splice modulation, RNA degradation, direct RNA binding, covalent targeting, epitranscriptomics, and condensate biology. You'll gain practical insight into what's working, what's failing, and where the field is heading next.
Challenges We Help Solve
Identifying Functional RNA Targets Worth Pursuing
Move beyond target ligandability alone and understand how leading teams are selecting RNA targets with the greatest biological relevance, tractability, and therapeutic potential.
Expanding Beyond Splice Modulation
Discover how innovators are leveraging direct RNA binding, RNA degradation, translation inhibition, covalent binders, condensate biology, and epitranscriptomics to unlock new therapeutic opportunities.
Overcoming Selectivity Challenges
Learn how organizations are assessing target engagement, off-target effects, and functional activity to build confidence in candidate progression.
Finding Novel Chemical Space
Benchmark strategies for exploring chemically diverse scaffolds and avoiding increasingly crowded and competitive RNA-targeting chemistry landscapes.
Advancing Programs Toward the Clinic
Hear lessons learned from companies moving from discovery into preclinical and clinical development to de-risk your own development strategy.
Priority Sessions for Biotech Teams
Identifying Functional RNA Targets at Scale
Workshop A: Identifying Functional RNA Targets at Scale to Prioritize Therapeutically Relevant Discovery Hypothesis
Pre-Conference Day
Speakers:
- Dalya Gartzman, Chief Executive Officer & Co-Founder, Renasis Bio
- Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics
- Stefan Schiesser, Director, Medicinal Chemistry, AstraZeneca
Discover how leading biotech teams are distinguishing biologically meaningful RNA targets from targets that are simply ligandable, while implementing scalable approaches to improve discovery success and reduce wasted screening efforts.
Expanding RNA-Focused Chemical Space
Workshop C: Exploring RNA-Focused Chemical Space Beyond Known Chemotypes to Inspire New Hit Discovery Strategies
Pre-Conference Day
Speakers:
- Lukasz Olenginski, Senior Scientist, Screening & Assay Development, Molecular Horizon
- Robert Batey, Professor, Department of Biochemistry, University of Colorado Boulder
Learn how innovators are breaking away from crowded RNA-targeting chemistry, discovering novel scaffolds, and creating differentiated opportunities across splice modulation, degradation, translation inhibition, and direct RNA binding programs.
Advancing RNA-Targeted Programs Toward the Clinic
Advancing Oral Splice-Modulating Small Molecules Toward Clinical Development for Rare Neurodegenerative Diseases
Conference Day One
Speaker:
- Sridhar Narayan, Vice President, Medicinal Chemistry, ReviR Therapeutics
Gain practical insights into optimizing activity, selectivity, and translational confidence while navigating the progression of RNA-targeted small molecules from discovery toward IND-enabling studies and clinical evaluation.
Benchmark Your Strategy Against Peers
Questions you could ask your peers to benchmark against them:
How are they identifying functionally relevant versus merely ligandable targets?
What screening approaches are generating the most actionable hits?
How are teams assessing selectivity before entering development?
Which emerging modalities are attracting the most investment?
What evidence is needed to convince pharma partners?
What Past Attendees Say
This meeting is the main chance each year for all of the thought leaders in drugging RNA with small molecules to get in one room and exchange ideas. If you want to know what the latest approaches are to cracking the RNA-drugging problem, you’ll find them here.
The summit was both informative and inspiring, giving me valuable insights and ideas that I can bring back to my own work.
Turn RNA Innovation Into Action
From identifying functional RNA targets and optimizing lead compounds to securing strategic partnerships and evaluating new modalities, this summit is designed to help you overcome the challenges facing the next generation of RNA-targeted therapeutics.
Explore the latest scientific advances, connect with peers facing similar challenges, and leave with practical insights you can immediately apply to your research, pipeline, and business strategy.
Secure your place today or explore the full agenda to discover the sessions most relevant to you.